Cargando…

SPOCK2 and SPRED1 function downstream of EZH2 to impede the malignant progression of lung adenocarcinoma in vitro and in vivo

Enhancer of zeste homolog 2 (EZH2) is an important epigenetic regulator, and is associated with the malignant progression of lung cancer. However, the mechanisms of EZH2 on lung adenocarcinoma (LUAD) remain unclear. The relationship between EZH2 and SPOCK2 or SPRED1 was confirmed by dual-luciferase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Fan, Xiaoxi, Jiang, Changrui, Xu, Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832413/ https://www.ncbi.nlm.nih.gov/pubmed/36629984 http://dx.doi.org/10.1007/s13577-023-00855-0

Ejemplares similares

Java testing with Spock
por: Kapelonis, Konstantinos
Publicado: (2016)

Progress in experimental research on SPRED protein family
por: Gong, Jian, et al.
Publicado: (2020)

SPRED proteins and their roles in signal transduction, development, and malignancy
por: Lorenzo, Claire, et al.
Publicado: (2020)

SPOCK2 Serves as a Potential Prognostic Marker and Correlates With Immune Infiltration in Lung Adenocarcinoma
por: Zhao, Jinming, et al.
Publicado: (2020)

Spock, 'frito' en segundos
Publicado: (2010)

Mechanism of prognostic marker SPOCK3 affecting malignant progression of prostate cancer and construction of prognostic model
por: Luo, Jiawen, et al.
Publicado: (2023)

Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder
por: Oda, Shinsuke, et al.
Publicado: (2021)

SPOCK2 gene expression is downregulated in pancreatic ductal adenocarcinoma cells and correlates with prognosis of patients with pancreatic cancer
por: Aghamaliyev, Ughur, et al.
Publicado: (2023)

SPOCK2 Promotes the Malignant Behavior of Ovarian Cancer via Regulation of the Wnt/β-Catenin Signaling Pathway
por: Zhao, Shanshan, et al.
Publicado: (2022)

EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)

Complete Genome of Bacillus thuringiensis Myophage Spock
por: Maroun, Justin W., et al.
Publicado: (2013)

SPOCK1 Promotes the Development of Hepatocellular Carcinoma
por: Váncza, Lóránd, et al.
Publicado: (2022)

Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR
por: Yan, Wupeng, et al.
Publicado: (2020)

Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma
por: Luo, Wenyi, et al.
Publicado: (2022)

Spred2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by impairing ERK signaling
por: Wang, Hao, et al.
Publicado: (2020)

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer
por: Kachroo, N, et al.
Publicado: (2013)

The SPRED1 Variants Repository for Legius Syndrome
por: Sumner, Kelli, et al.
Publicado: (2011)

Corrigendum: SPOCK1 promotes the development of hepatocellular carcinoma
por: Váncza, Lóránd, et al.
Publicado: (2023)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022)

Spred-2 Deficiency Exacerbates Lipopolysaccharide-Induced Acute Lung Inflammation in Mice
por: Xu, Yang, et al.
Publicado: (2014)

A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation
por: Takahashi, Sakuma, et al.
Publicado: (2016)

SAPAP3, SPRED2, and obsessive-compulsive disorder: the search for fundamental phenotypes
por: Rajkumar, Ravi Philip
Publicado: (2023)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo
por: Tang, Shou-Hung, et al.
Publicado: (2014)

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
por: Uebel, Anne, et al.
Publicado: (2023)

The role of EZH2 in tumour progression
por: Chang, C-J, et al.
Publicado: (2012)

The Sprouty/Spred family as tumor suppressors: Coming of age
por: Kawazoe, Tetsuro, et al.
Publicado: (2019)

Spock, up and running: writing expressive tests in Java and Groovy
por: Fletcher, Rob
Publicado: (2017)

Stromal SPOCK1 supports invasive pancreatic cancer growth
por: Veenstra, Veronique L., et al.
Publicado: (2017)

SPOCK1 Overexpression Suggests Poor Prognosis of Ovarian Cancer
por: Váncza, Lóránd, et al.
Publicado: (2023)

Proteoglycan SPOCK1 as a Poor Prognostic Marker Promotes Malignant Progression of Clear Cell Renal Cell Carcinoma via Triggering the Snail/Slug-MMP-2 Axis-Mediated Epithelial-to-Mesenchymal Transition
por: Lin, Yung-Wei, et al.
Publicado: (2023)

Spred-2 Suppresses Aorta-Gonad-Mesonephros Hematopoiesis by Inhibiting MAP Kinase Activation
por: Nobuhisa, Ikuo, et al.
Publicado: (2004)

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells
por: Yang, Yuefeng, et al.
Publicado: (2015)

Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
por: Jiao, Mi, et al.
Publicado: (2022)

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo
por: Kuang, Yan, et al.
Publicado: (2017)

PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression
por: Wan, Junhu, et al.
Publicado: (2015)

EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD
por: Vella, Serena, et al.
Publicado: (2013)

Sprouty2 and Spred1-2 Proteins Inhibit the Activation of the ERK Pathway Elicited by Cyclopentenone Prostanoids
por: García-Domínguez, Carlota A., et al.
Publicado: (2011)

SPOCK1 Overexpression Confers a Poor Prognosis in Urothelial Carcinoma
por: Ma, Li-Jung, et al.
Publicado: (2016)

SPOCK1 promotes tumor growth and metastasis in human prostate cancer
por: Chen, Qi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a4n548au6i1er316bsvqfb3u9c